公募基金方面，本期较上一期持股增加的公募基金共计2个，包括泰康丰盈债券A、路博迈中国医疗健 康股票发起A，持股增加占比小幅上涨。本期较上一季度持股减少的公募基金共计3个，包括国泰医药 健康股票A、国泰大健康股票A、泰康医疗健康股票发起A，持股减少占比达0.24%。本期较上一季度新 披露的公募基金共计4个，包括南方中证1000ETF、鑫元聚鑫收益增强A、鑫元鑫领航混合A、红塔红土 盛商一年定期开放债券A。本期较上一季未再披露的公募基金共计7个，主要包括中欧医疗健康混合A、 南方 中证500 ETF、汇丰晋信新动力混合A、财通资管健康产业混合A、汇添富中证 互联网 医疗指数 (LOF)A等。 险资方向，本期较上一季度持股减少的险资共计1个，即中国人寿保险股份有限公司-传统-普通保险产 品-005L-CT001沪，持股减少占比小幅下跌。 2025年8月26日， 老百姓 (603883.SH)发布2025年半年度报告。截至2025年8月25日，共有14个机构投资 者披露持有老百姓A股股份，合计持股量达3.94亿股，占老百姓总股本的51.87%。其中，前十大机构投 资者包括老百姓医药集团有限公司、泽星投资有限公司、香港 ...

Core Viewpoint - The report highlights a significant institutional ownership in the company, with a total of 14 institutional investors holding 3.94 billion shares, representing 51.87% of the total share capital as of August 25, 2025 [1] Group 1: Institutional Ownership - A total of 14 institutional investors disclosed their holdings in the company, with a combined shareholding of 3.94 billion shares, accounting for 51.87% of the total share capital [1] - The top ten institutional investors collectively hold 51.84% of the shares, with a decrease of 3.21 percentage points compared to the previous quarter [1] Group 2: Public Fund Holdings - Two public funds increased their holdings during this period, while three public funds reduced their holdings, with a decrease rate of 0.24% [2] - Four new public funds disclosed their holdings this period, while seven public funds were not disclosed compared to the previous quarter [2] Group 3: Insurance Capital Holdings - One insurance capital entity, China Life Insurance Co., Ltd., reported a slight decrease in holdings during this period [2]

Group 1 - The State Council Information Office will hold two press conferences on August 26, focusing on the achievements of high-quality energy development during the 14th Five-Year Plan and details about the 25th China International Investment and Trade Fair [1] Group 2 - Domestic refined oil prices are expected to see their seventh decrease of the year, with the new pricing window opening on August 26. This follows a total of sixteen pricing adjustments this year, resulting in a reduction of 225 yuan per ton for gasoline and 215 yuan per ton for diesel compared to the end of last year [2] Group 3 - On August 26, a total of 7 companies will have their restricted shares unlocked, with a total of 149 million shares and a combined market value of 6.802 billion yuan. The companies with the largest unlock volumes include Zhenhua Wind Power, Jiacheng International, and Xiaofang Pharmaceutical [3] Group 4 - Eighteen companies disclosed progress on stock repurchases on August 26, with 8 companies announcing new repurchase plans. The highest repurchase amounts were announced by Paislin, Tongrun Equipment, and Laobaixing, with planned repurchases of 26.0698 million yuan, 22.4273 million yuan, and 14.8894 million yuan respectively [4]

第一条 为明确审计工作的性质、使命和目标，明确老百姓大药房连锁股份有限公司（以 下简称"公司"）内部审计机构的职责与权限，确保董事会对经理层的有效监督，发挥内部 审计在强化内部控制、改善经营管理、提高经济效益中的促进和保证作用，以维护投资者的 权益，实现审计的制度化和规范化，根据《中华人民共和国公司法》《中华人民共和国审计 法》《上海证券交易所股票上市规则》《上海证券交易所上市公司自律监管指引第 1 号—— 规范运作》和《老百姓大药房连锁股份有限公司章程》（以下简称"《公司章程》"），特 制定本制度。 第二条 本制度所称内部审计，是指公司内部审计机构或人员在法律法规、公司规定和董 事会批准范围内，通过运用系统、规范的方法，对公司内部控制和风险管理的适当性和有效 性以及业务活动运行的效率和效果等开展的独立、客观的评价和咨询活动。 第三条 内部审计应遵循"独立、客观、公正"的原则，保证其工作合法、合理、有效， 完善公司内部约束机制，加强内部管理，提高经济效益。 第二章 内部审计机构及人员 老百姓大药房连锁股份有限公司 内部审计制度 （二〇二五年八月二十五日，第五届董事会第十次会议审议通过） 第一章 总则 第四条 ...

董事会秘书负责办理上市公司内幕信息知情人的登记入档和报送事宜，证 券事务部为公司内幕信息的管理、登记、披露及备案的日常工作部门。董事长 与董事会秘书应当对内幕信息知情人档案的真实、准确和完整签署书面确认意 见。 第三条 公司的董事、高级管理人员和公司的各部门、子公司及相关人员 都应配合做好内幕信息的登记备案工作，并采取必要措施，在内幕信息公开前 将该信息的内幕知情人范围控制在最小范围内。 老百姓大药房连锁股份有限公司 内幕信息知情人登记管理制度 （二〇二五年八月二十五日，第五届董事会第十次会议审议通过） 第一章 总则 第一条 为规范老百姓大药房连锁股份有限公司（以下简称"公司"）的内 幕信息管理，加强内幕信息保密工作，维护信息披露公开、公平、公正的原则， 防范内幕信息泄露及内幕信息交易，根据《中华人民共和国公司法》《中华人民 共和国证券法》《上市公司治理准则》《上市公司信息披露管理办法》《上海证券交 易所股票上市规则》《上市公司监管指引第5号——上市公司内幕信息知情人登记 管理制度》《上海证券交易所上市公司自律监管指引第2号——信息披露事务管理》 等有关法律、法规、以及《公司章程》的规定，特制定本制度。 第二 ...

Core Points - The document outlines the information disclosure management system of the company, aiming to ensure timely, fair, truthful, accurate, and complete information disclosure to protect investors' rights [1][2][3] - The company is committed to proactive disclosure of significant information that may impact stakeholders' decisions, while safeguarding sensitive financial data and trade secrets [1][2] Group 1: General Principles - The company establishes information disclosure principles in accordance with relevant laws and regulations, including the Company Law and Securities Law [1][2] - Information disclosure must be conducted through designated channels, ensuring accessibility for the public [1][2] Group 2: Disclosure Formats and Content - Regular reports, including annual and interim reports, must be disclosed within specified timeframes, with annual reports due within four months after the fiscal year-end and interim reports within two months after the first half of the fiscal year [2][3] - The content of annual reports includes company basic information, major accounting data, stock and bond issuance details, shareholder information, and significant events affecting the company [2][3][4] Group 3: Responsibilities and Procedures - The board of directors must approve regular reports, and financial information must be audited by a qualified accounting firm [4][5] - The company must disclose significant events that could impact stock prices immediately, detailing the event's cause, current status, and potential effects [6][12] Group 4: Management of Disclosure - The company's securities affairs department is responsible for managing daily disclosure tasks and ensuring compliance with regulations [34][35] - The board secretary plays a crucial role in coordinating disclosure activities and ensuring that all relevant information is accurately reported [35][36] Group 5: Confidentiality and Compliance - Individuals with access to undisclosed information are considered insiders and must maintain confidentiality to prevent unauthorized trading [58][59] - The company must implement measures to control the dissemination of insider information and ensure compliance with regulatory requirements [60][61]

Core Viewpoint - The legal opinion letter from Hunan Qiyuan Law Firm confirms that the company has obtained necessary approvals for the repurchase and cancellation of restricted stocks, as well as adjustments to repurchase prices, in accordance with relevant laws and regulations [1][12]. Group 1: Approval and Authorization - The company has received independent opinions from its independent directors regarding the 2022 Restricted Stock Incentive Plan and related proposals [5][7]. - The board of directors has been authorized to handle matters related to the incentive plan, including adjustments to repurchase prices and the cancellation of restricted stock for certain individuals [6][8]. Group 2: Repurchase and Adjustment Details - The company plans to repurchase and cancel a total of 1,205,377 shares of restricted stock due to the departure of 32 incentive plan participants and failure to meet performance targets [9][10]. - The repurchase price for the restricted stocks has been adjusted from 11.685 yuan to 11.605 yuan per share due to a cash dividend distribution of 0.08 yuan per share [11]. Group 3: Funding and Compliance - The funding for the repurchase will come from the company's own funds, which complies with the relevant regulations [11][12]. - The company must complete legal procedures for changes in registered capital and amend its articles of association as required by law [12].

Core Viewpoint - The company has adjusted the repurchase price of its 2022 restricted stock incentive plan, reflecting changes due to cash dividends and compliance with relevant regulations [5][6][7]. Decision Procedures and Disclosure - The company held board and supervisory meetings to review and approve the adjustment of the repurchase price, ensuring independent opinions were provided by independent directors [1][2]. - The company conducted internal announcements and did not receive any objections during the public notice period [2]. Adjustment Reasons and Results - The adjustment of the repurchase price was necessitated by the distribution of cash dividends of 0.08 yuan per share, which was completed on July 14, 2025 [5][6]. - The repurchase price was adjusted from 11.685 yuan per share to 11.605 yuan per share, in accordance with the incentive plan's provisions [6]. Impact on the Company - The adjustment aligns with the relevant laws and regulations, ensuring no harm to the company or its shareholders, and is not expected to materially affect the company's financial status or operational results [6][7]. Supervisory and Legal Opinions - The supervisory board confirmed that the adjustment complies with the necessary legal frameworks and does not harm the interests of the company or its shareholders [7]. - Legal opinions from Hunan Qiyuan Law Firm affirmed that the adjustment has received the required approvals and adheres to relevant regulations [7].

Group 1 - The company announced the repurchase and cancellation of 1,205,377 restricted stocks from its 2022 incentive plan due to 32 individuals leaving for personal reasons and performance not meeting standards [1] - Following the repurchase, the company's registered capital will decrease by 1,205,377 yuan [1] - Creditors have a 30-day period from receiving the notice, or 45 days from the announcement date, to claim debts or request guarantees [1][2] Group 2 - Creditors must submit written requests along with relevant documentation to the company to claim debts or seek guarantees [2]

Core Viewpoint - The company has decided to repurchase and cancel a total of 1,205,377 restricted shares from its 2022 incentive plan due to the departure of 32 employees and underperformance in meeting company-level targets [1][7][8] Summary by Sections 1. Background of the Repurchase - The company held meetings on August 25, 2025, where the board and supervisory committee approved the repurchase of remaining restricted shares from the 2022 incentive plan [1] - The total amount for the repurchase is 14,889,399.25 yuan, sourced from the company's own funds [6] 2. Details of the Incentive Plan - The 2022 incentive plan included provisions for the approval and implementation of the plan, which was publicly disclosed and reviewed by independent directors [2][3] - The plan faced adjustments due to the departure of employees and performance issues, leading to the decision to cancel the restricted shares [5][7] 3. Repurchase Details - The repurchase involves 1,205,377 shares, with a repurchase price of 11.605 yuan per share, which includes interest from the People's Bank of China [6] - The repurchase will not affect the company's financial status or operational results significantly [7] 4. Impact on Share Structure - Following the repurchase, the company's total share structure will change, with the number of restricted shares decreasing to zero, while the number of unrestricted shares remains at 758,890,236 [6] 5. Future Actions - The company will proceed with necessary legal and regulatory procedures related to the repurchase and will ensure timely disclosure of information [8]